Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Nippon Shinyaku Launches Open Innovation-Driven Drug Discovery Hub in US
January 10, 2023
- Fujifilm US Subsidiary Licenses iPSC Platform to Novo
January 10, 2023
- US Federal Circuit Nixes Lexiscan Patent Infringement, Astellas to File Appeal
January 6, 2023
- Dayvigo Tops HP Ranking, Twymeeg Most Promoted in GP Market 5 Months Running in November: Intage
January 6, 2023
- Shionogi Reports 2 Serious Side Effect Cases in Xocova Update
January 6, 2023
- Xocova Filed for Conditional Approval in South Korea
January 6, 2023
- Enhertu’s Application for NSCLC Use Accepted in Europe: Daiichi Sankyo
January 6, 2023
- Moderna Snags Tokyo Upstart in Its 1st M&A Deal, Staff to Join Japan Unit
January 6, 2023
- Creditors Approve Nichi-Iko’s Turnaround Scheme, Grants Debt Waiver of 98.5 Billion Yen
January 5, 2023
- Steve Sugino Becomes New CEO of BMS Japan
January 5, 2023
- Japan Likely to See Generic Listing for Azilva, Zytiga in 2023; Xarelto AG Rivals Too
January 5, 2023
- Sun Pharma Japan Gearing Up Sales of Flagship Dermatology Med Ilumya: President
December 28, 2022
- RaQualia, Veritas Seal mRNA Drug Discovery Collaboration
December 28, 2022
- PeptiDream, Lilly Ink Collab with Up to US$1.2 Billion in Milestones
December 27, 2022
- Estimated 4,640 Patients Took Xocova by Dec. 18: Shionogi
December 27, 2022
- SymBio, Eagle Take Pfizer Japan to Court after Treakisym Gx Launch
December 27, 2022
- Towa Hopes to Resume Meropenem 0.5 g Shipment in March
December 27, 2022
- AnGes to Invest US$2 Million in Canada’s Vasomune
December 27, 2022
- CureApp to Kick Off Japan PIII Study of Alcohol Addiction Therapeutic App in January
December 27, 2022
- Eisai Begins Data Submission for AD Med Lecanemab in China
December 26, 2022
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…